Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASMBS Highlights New Developments in Bariatric Surgery

Executive Summary

A record-breaking attendance at 2010's meeting of the American Society for Metabolic and Bariatric Surgery marked the growing interest in new ways to address the issue of obesity. Currently, less than 1% of a potential US patient population of 15 million who might benefit from bariatric surgery actually undergo the procedure, and surgeons are scrambling to understand why and to identify new, less invasive approaches that might help them better penetrate this enormous patient pool.

You may also be interested in...



Obesity And Diabetes: Toward A Surgical Solution: An Interview With Francesco Rubino, MD

A new position statement from the International Diabetes Federation that endorses bariatric surgery as a medically indicated therapeutic option for diabetes represents an important philosophical shift for this field, according to Francesco Rubino, MD, chief of gastrointestinal metabolic surgery at Weill Cornell Medical College.

Obesity 2011: Back To Basics In Bariatrics

The market for obesity products has blockbuster potential, but it’s proven an elusive target for the medical device industry. The challenging regulatory environment, weak economy, and skittish investors have slowed the number of product launches in recent years, and there have been some high-profile setbacks for several potential weight loss therapies. But now, a "back to basics" movement, focused on understanding the physiological triggers behind obesity rather than simply restricting food intake, hopes to spur development of more effective minimally invasive weight loss solutions.

New Avenues in Neuromodulation

Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT035369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel